## STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page2/Line11-14	Abstract/Paragraph2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page2/Line25-26	Abstract/Paragraph4
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page1/Line11-14	Introduction/Paragraph1
Objectives	3	State specific objectives, including any prespecified hypotheses	Page2/Line18-20	Introduction/Paragraph2
Methods				
Study design	4	Present key elements of study design early in the paper	Page2/Line20-25	Introduction/Paragraph2
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page2/Line20-25	Page2/Line20-25
Participants	6	(a) <b>Cohort study</b> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <b>Case-control study</b> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <b>Cross-sectional study</b> —Give the eligibility criteria, and the sources and methods of selection of participants	Page2/Line30-33	Methods/Paragraph1
		(b) <b>Cohort study</b> —For matched studies, give matching criteria and number of exposed and unexposed <b>Case-control study</b> —For matched studies, give matching criteria and the number of controls per case	Page2/Line30-33	Methods/Paragraph1
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page3/Line4-6	Methods/Paragraph2
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page3/Line21-25	Methods/Paragraph3
Bias	9	Describe any efforts to address potential sources of bias	Page3/Line21-25	Methods/Paragraph3
Study size	10	Explain how the study size was arrived at	Page2/Line30-33	Methods/Paragraph1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	N/A	-

12	(a) Describe all statistical methods, including those used to control for confounding	Page3/Line21-25	Methods/Paragraph3
	(b) Describe any methods used to examine subgroups and interactions	N/A	-
	(c) Explain how missing data were addressed	N/A	-
	(d) Cohort study—If applicable, explain how loss to follow-up was addressed  Case-control study—If applicable, explain how matching of cases and controls was addressed  Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy	Page2/Line30-33	Methods/Paragraph1
	(e) Describe any sensitivity analyses	N/A	-
•			
13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page2/Line30-36	Methods/Paragraph1
	(b) Give reasons for non-participation at each stage	N/A	-
	(c) Consider use of a flow diagram	N/A	-
14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page2/Line30-36	Methods/Paragraph1
	(b) Indicate number of participants with missing data for each variable of interest	N/A	-
	(c) Cohort study — Summarise follow-up time (eg, average and total amount)	Page2/Line7-10	Methods/Paragraph1
15*	Cohort study — Report numbers of outcome events or summary measures over time	Page2/Line15-22	Results/Paragraph1
	Case-control study—Report numbers in each exposure category, or summary measures of exposure	N/A	-
	Cross-sectional study—Report numbers of outcome events or summary measures	N/A	
16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	N/A	-
	(b) Report category boundaries when continuous variables were categorized	N/A	-
	(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	-
17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A	-
•			•
18	Summarise key results with reference to study objectives	Page4/Line30-32	Methods/Paragraph4
19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	N/A	-
	13* 14* 15* 16	(b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) Cohort study—If applicable, explain how loss to follow-up was addressed Case-control study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, explain how matching of cases and controls was addressed (c) Describe any sensitivity analyses  13*  (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram  14*  (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Cohort study—Summarise follow-up time (eg, average and total amount)  15°  Cohort study—Report numbers of outcome events or summary measures over time  Case-control study—Report numbers in each exposure category, or summary measures  16  (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period  17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	(c) Explain how missing data were addressed (d) Cohort study—If applicable, explain how loss to follow-up was addressed (d) Cohort study—If applicable, explain how loss to follow-up was addressed Case-control study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, explain how matching of cases and controls was addressed (e) Describe any sensitivity analyses  N/A  13*  (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram  N/A  14*  (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Cohort study—Summarise follow-up time (eg, average and total amount)  Page2/Linc7-10  15*  Cohort study—Report numbers of outcome events or summary measures over time  Case-control study—Report numbers of outcome events or summary measures of exposure  N/A  Cross-sectional study—Report numbers of outcome events or summary measures (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period  N/A  Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses  Page4/Linc30-32  Page4/Linc30-32  Page4/Linc30-35

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page6/Line28-32	Discussion/Paragraph4				
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page6/Line28-32	Discussion/Paragraph4				
Other information								
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page7/Line1-4	Acknowledgments/Paragra ph1				

<sup>\*</sup>Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article Information: https://dx.doi.org/10.21037/jgo-21-339

<sup>\*</sup>As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.